The Neuro's Virtual Integrated Patient Platform receives major funding
Brain Canada support will help accelerate the discovery of new treatments for brain and nervous system disorders
An innovative project led by Dr. Guy Rouleau at The Neuro has received major funding from Brain Canada, one of four platforms that are advancing treatment discovery across a wide range of neurological disorders. In total the four platforms are being supported with a $8,926,500 investment.
Dr. Rouleau鈥檚 project, The Neuro's Virtual Integrated Patient Platform (NeuroVIP), brings together patient data, biological samples, and powerful research tools into a single, Open Science platform that is accessible to scientists in Canada and worldwide.
The platform is built on the combined strengths of five specialized research facilities at The Neuro. The Clinical Research Unit (CRU) recruits patients for clinical trials and research studies. The Clinical Biospecimen Imaging and Genetic (C-BIG) repository collects and stores patient samples and data. The Early Drug Discovery Unit (EDDU) creates patient-derived stem cells and 3D 鈥渕ini-brains鈥� (organoids) that can be used to test potential treatments. The Neuro Bioinformatics Core (NBC) analyzes complex genetic and molecular data using advanced computing methods, while the Neuro Microscopy Core Facility (NMCF) provides cutting-edge imaging to study brain cells in detail.
Together, these resources allow researchers to link clinical information with genetic, cellular, and imaging data in ways that have never been possible before.
"These platforms show the power of investing in shared infrastructure and open access," said Viviane Poupon, President and CEO of Brain Canada. "From RNA therapeutics and molecular profiling to integrated patient data and living human tissue, they are helping move discoveries into earlier diagnoses, better treatments, and meaningful improvements in brain health for people across Canada."